First Dual Monitoring Wearable
FDA Authorizes First Wearable to Continuously Monitor Glucose and Ketones Together
Anonymous
Key Points
1
The FDA granted authorization via the De Novo premarket pathway, with Abbott presenting accuracy data from six clinical studies enrolling more than 600 participants to support the decision.
2
FDA director Michelle Tarver called the authorization a 'breakthrough for the safety of children and adults living with diabetes.'
3
The Libre Duo 10 Day is the first wearable approved in the United States to continuously monitor ketone levels, and the first device globally to continuously monitor both glucose and ketones in a single system.
4
The FDA notes that ketone information should be interpreted in the context of glucose readings and symptoms, underscoring the link to diabetic ketoacidosis risk.
The FDA has authorized Abbott's Libre Duo 10 Day, the first wearable device to continuously monitor both glucose and ketone levels in a single system UPI. The device measures interstitial fluid every minute over 10 days and sends readings to a smartphone with automatic alerts for dangerous ketone levels Reuters. This dual monitoring helps prevent diabetic ketoacidosis — a life-threatening condition — for people aged 2 and older HCPLive.
First Device to Track Ketones and Glucose Together
Abbott presented accuracy data from six clinical studies with over 600 participants to support FDA approval HCPLive. The Libre Duo 10 Day is the first wearable approved in the US to continuously monitor ketone levels. It is also the first device globally to track both glucose and ketones in real time UPI. FDA director Michelle Tarver called it a 'breakthrough for the safety of children and adults living with diabetes' Reuters.
Why Ketone Monitoring Matters for Diabetes Care
Diabetic ketoacidosis happens when the body breaks down fat too quickly, creating dangerous acid levels in the blood. High ketone readings combined with high blood sugar signal immediate risk. The FDA notes that ketone information should be interpreted alongside glucose readings and symptoms HCPLive. Real-time alerts let patients and doctors act fast to prevent this life-threatening emergency.
FDA Fast-Tracked Approval Using De Novo Pathway
Abbott used the FDA's De Novo premarket pathway, a streamlined route for novel devices with no existing equivalent HCPLive. This pathway allows breakthrough technologies to reach patients faster while maintaining safety standards. The authorization required robust clinical data — which Abbott delivered from its six studies involving hundreds of participants Reuters. The company plans to launch Libre Duo 10 Day in the United States later this year UPI.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
48
Reach
58
A
AnonymousAuthor
